Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
The development of inhibitors against therapeutically administered factors VIII or IX is actually the most challenging complication of hemophilia patients with inhibitors. The introduction of bypassing agents (i.e., activated prothrombin complex concentrates and recombinant activated factor VII [rFVIIa]) has dramatically improved the management of bleeding episodes in such patients. Over the last decade, there have been increasing reports on the ability of bypassing agents to prevent surgical, joint, or other bleeds in inhibitor patients. The published data on the use of rFVIIa as a prophylactic treatment in hemophilia patients with inhibitors are reviewed in this article.
Franchini
Massimo
M
Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. massimo.franchini@azosp.vr.it
Manzato
Franco
F
Salvagno
Gian Luca
GL
Montagnana
Martina
M
Zaffanello
Marco
M
Lippi
Giuseppe
G
D016063:Blood Loss, Surgical / Q000517:prevention & control; D015942:Factor VIIa / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy* / Q000517:prevention & control; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa